FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2962251162> ?p ?o ?g. }

• W2962251162 endingPage "426" @default.
• W2962251162 startingPage "419" @default.
• W2962251162 abstract "Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged zoledronate (ZOL) in the setting of CKD but how this accumulation is retained/lost over time is unclear. Furthermore, it is unknown if alternative dosing approaches can modulate accumulation in the setting of CKD.To address these two questions normal (NL) and Cy/+ (CKD) rats were divided into control groups (no dosing), a single dose of a fluorescent-tagged ZOL (FAM-ZOL), a single dose of non-labelled zoledronate (ZOL) or ten weekly doses of FAM-ZOL each at 1/10th the dose of the single dose group. Half of the CKD animals in each group were provided water with 3% calcium in drinking water (CKD + Ca) to suppress PTH and remodeling. At 30 or 35 weeks of age, serum, tibia, ulna, radius, vertebra, femora, and mandible were collected and subjected to assessment methods including biochemistry, dynamic histomorphometry and multi-spectral fluorescence levels (using IVIS SpectrumCT).FAM-ZOL did not significantly reduce bone remodeling in either NL or CKD animals while Ca supplementation in CKD produced remodeling levels comparable to NL. At five- and ten-weeks post-dosing, both CKD and CKD + Ca groups had higher levels of FAM-ZOL in most, but not all, skeletal sites compared to NL with no difference between the two CKD groups suggesting that the rate of remodeling did not affect skeletal retention of FAM-ZOL. Fractionating the FAM-ZOL into ten weekly doses led to 20-32% less (p < 0.05) accumulation/retention of compound in the vertebra, radius, and ulna compared to administration as a single dose.The rate of bone turnover does not have significant effects on levels of FAM-ZOL accumulation/retention in animals with CKD. A lower dose/more frequent administration paradigm results in lower levels of accumulation/retention over time. These data provide information that could better inform the use of bisphosphonates in the setting of CKD in order to combat the dramatic increase in fracture risk." @default.
• W2962251162 created "2019-07-23" @default.
• W2962251162 creator A5000603296 @default.
• W2962251162 creator A5002053098 @default.
• W2962251162 creator A5017335154 @default.
• W2962251162 creator A5031395758 @default.
• W2962251162 creator A5044149723 @default.
• W2962251162 creator A5058494008 @default.
• W2962251162 creator A5061325152 @default.
• W2962251162 creator A5063855053 @default.
• W2962251162 creator A5071706141 @default.
• W2962251162 creator A5074659892 @default.
• W2962251162 creator A5080453305 @default.
• W2962251162 date "2019-10-01" @default.
• W2962251162 modified "2023-10-14" @default.
• W2962251162 title "Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing" @default.
• W2962251162 cites W1972433532 @default.
• W2962251162 cites W1982018040 @default.
• W2962251162 cites W1983096989 @default.
• W2962251162 cites W1992163212 @default.
• W2962251162 cites W1996281846 @default.
• W2962251162 cites W1997190237 @default.
• W2962251162 cites W2009897665 @default.
• W2962251162 cites W2020909365 @default.
• W2962251162 cites W2043817882 @default.
• W2962251162 cites W2047856826 @default.
• W2962251162 cites W2082161313 @default.
• W2962251162 cites W2096425957 @default.
• W2962251162 cites W2116727386 @default.
• W2962251162 cites W2127963150 @default.
• W2962251162 cites W2133325671 @default.
• W2962251162 cites W2133650478 @default.
• W2962251162 cites W2137043925 @default.
• W2962251162 cites W2138171217 @default.
• W2962251162 cites W2140285293 @default.
• W2962251162 cites W2158222136 @default.
• W2962251162 cites W2170998246 @default.
• W2962251162 cites W2172159264 @default.
• W2962251162 cites W2606034293 @default.
• W2962251162 cites W2609761376 @default.
• W2962251162 cites W2700576091 @default.
• W2962251162 cites W2792154527 @default.
• W2962251162 cites W2807861774 @default.
• W2962251162 cites W4237871677 @default.
• W2962251162 cites W4256653765 @default.
• W2962251162 doi "https://doi.org/10.1016/j.bone.2019.07.007" @default.
• W2962251162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6708715" @default.
• W2962251162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31299384" @default.
• W2962251162 hasPublicationYear "2019" @default.
• W2962251162 type Work @default.
• W2962251162 sameAs 2962251162 @default.
• W2962251162 citedByCount "4" @default.
• W2962251162 countsByYear W29622511622020 @default.
• W2962251162 countsByYear W29622511622022 @default.
• W2962251162 crossrefType "journal-article" @default.
• W2962251162 hasAuthorship W2962251162A5000603296 @default.
• W2962251162 hasAuthorship W2962251162A5002053098 @default.
• W2962251162 hasAuthorship W2962251162A5017335154 @default.
• W2962251162 hasAuthorship W2962251162A5031395758 @default.
• W2962251162 hasAuthorship W2962251162A5044149723 @default.
• W2962251162 hasAuthorship W2962251162A5058494008 @default.
• W2962251162 hasAuthorship W2962251162A5061325152 @default.
• W2962251162 hasAuthorship W2962251162A5063855053 @default.
• W2962251162 hasAuthorship W2962251162A5071706141 @default.
• W2962251162 hasAuthorship W2962251162A5074659892 @default.
• W2962251162 hasAuthorship W2962251162A5080453305 @default.
• W2962251162 hasBestOaLocation W29622511622 @default.
• W2962251162 hasConcept C126322002 @default.
• W2962251162 hasConcept C126894567 @default.
• W2962251162 hasConcept C134018914 @default.
• W2962251162 hasConcept C159641895 @default.
• W2962251162 hasConcept C170033053 @default.
• W2962251162 hasConcept C181389837 @default.
• W2962251162 hasConcept C2776541429 @default.
• W2962251162 hasConcept C2777251235 @default.
• W2962251162 hasConcept C2777288759 @default.
• W2962251162 hasConcept C2778653478 @default.
• W2962251162 hasConcept C2780091579 @default.
• W2962251162 hasConcept C2909674915 @default.
• W2962251162 hasConcept C3018268312 @default.
• W2962251162 hasConcept C71924100 @default.
• W2962251162 hasConcept C98274493 @default.
• W2962251162 hasConceptScore W2962251162C126322002 @default.
• W2962251162 hasConceptScore W2962251162C126894567 @default.
• W2962251162 hasConceptScore W2962251162C134018914 @default.
• W2962251162 hasConceptScore W2962251162C159641895 @default.
• W2962251162 hasConceptScore W2962251162C170033053 @default.
• W2962251162 hasConceptScore W2962251162C181389837 @default.
• W2962251162 hasConceptScore W2962251162C2776541429 @default.
• W2962251162 hasConceptScore W2962251162C2777251235 @default.
• W2962251162 hasConceptScore W2962251162C2777288759 @default.
• W2962251162 hasConceptScore W2962251162C2778653478 @default.
• W2962251162 hasConceptScore W2962251162C2780091579 @default.
• W2962251162 hasConceptScore W2962251162C2909674915 @default.
• W2962251162 hasConceptScore W2962251162C3018268312 @default.
• W2962251162 hasConceptScore W2962251162C71924100 @default.
• W2962251162 hasConceptScore W2962251162C98274493 @default.
• W2962251162 hasFunder F4320306127 @default.

• next